Benitec Biopharma (BNTC) Accumulated Expenses (2019 - 2024)
Benitec Biopharma (BNTC) has disclosed Accumulated Expenses for 6 consecutive years, with $495000.0 as the latest value for Q3 2024.
- Quarterly Accumulated Expenses rose 7.61% to $495000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $495000.0 through Sep 2024, up 7.61% year-over-year, with the annual reading at $475000.0 for FY2024, 0.64% up from the prior year.
- Accumulated Expenses hit $495000.0 in Q3 2024 for Benitec Biopharma, up from $475000.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $523000.0 in Q4 2023 to a low of $197000.0 in Q3 2020.
- Historically, Accumulated Expenses has averaged $369944.4 across 5 years, with a median of $390500.0 in 2022.
- Biggest five-year swings in Accumulated Expenses: skyrocketed 54.55% in 2022 and later rose 0.64% in 2024.
- Year by year, Accumulated Expenses stood at $221000.0 in 2020, then surged by 45.25% to $321000.0 in 2021, then increased by 23.36% to $396000.0 in 2022, then skyrocketed by 32.07% to $523000.0 in 2023, then fell by 5.35% to $495000.0 in 2024.
- Business Quant data shows Accumulated Expenses for BNTC at $495000.0 in Q3 2024, $475000.0 in Q2 2024, and $517000.0 in Q1 2024.